CU Cancer Center Study Reveals Why Some AML Patients Don’t Respond to Standard Treatment

A global study led by the University of Colorado Cancer Center uncovered how gene mutations and leukemia cell maturity impact the effectiveness of the common AML treatment using venetoclax and hypomethylating agents. Findings, published in Blood Cancer Discovery, offer a roadmap for more personalized therapies and improved survival rates for patients with acute myeloid leukemia.